Edition:
United Kingdom

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

21.85USD
15 Dec 2017
Change (% chg)

$0.59 (+2.78%)
Prev Close
$21.26
Open
$21.20
Day's High
$21.99
Day's Low
$21.20
Volume
334,621
Avg. Vol
109,050
52-wk High
$26.43
52-wk Low
$15.57

Select another date:

Tue, Nov 7 2017

BRIEF-Retrophin reports third quarter 2017 financial results

* Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

BRIEF-Retrophin reports Q2 loss per share $0.34

* Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN

* Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan

Former Retrophin chairman says Martin Shkreli lied 'to my face'

Martin Shkreli was ousted as chief executive of drug company Retrophin Inc after disobeying directions from the board of directors and lying about it, the board's former chairman testified at Shkreli's securities fraud trial on Wednesday.

UPDATE 1-Former Retrophin chairman says Martin Shkreli lied 'to my face'

July 12 Martin Shkreli was ousted as chief executive of drug company Retrophin Inc after disobeying directions from the board of directors and lying about it, the board's former chairman testified at Shkreli's securities fraud trial on Wednesday.

CORRECTED-Former Retrophin chairman says Martin Shkreli lied 'to my face'

July 12 Martin Shkreli was ousted as chief executive of drug company Retrophin Inc after disobeying directions from the board of directors and lying about it, the board's former chairman testified at Shkreli's securities fraud trial on Wednesday.

CORRECTED-Lawyer for 'pharma bro' Shkreli paints ex-CEO as misunderstood genius

June 28 Martin Shkreli's lawyer did not run from his client's troubled public image, describing him as a misunderstood genius, as he began his defense in the former drug company executive's securities fraud trial on Wednesday.

Select another date: